{"id":48245,"date":"2025-08-12T09:35:02","date_gmt":"2025-08-12T06:35:02","guid":{"rendered":"https:\/\/www.egemtv.com\/?p=48245"},"modified":"2025-08-12T09:35:03","modified_gmt":"2025-08-12T06:35:03","slug":"kisiye-ozel-tarama-yontemleri-ve-hasta-takibi-kanserde-hayat-kurtariyor","status":"publish","type":"post","link":"https:\/\/www.egemtv.com\/?p=48245","title":{"rendered":"Ki\u015fiye \u00f6zel tarama y\u00f6ntemleri ve hasta takibi kanserde hayat kurtar\u0131yor"},"content":{"rendered":"<p>Kanser vakalar\u0131nda hastaya \u00f6zel tarama ve risk profili olu\u015fturulmas\u0131n\u0131n tedaviyi ba\u015far\u0131ya ula\u015ft\u0131rd\u0131\u011f\u0131n\u0131 belirten Denizli \u00d6zel Egekent Hastanesi \u0130\u00e7 Hastal\u0131klar\u0131 Uzman\u0131 Dr. Ahmet Bilge, &#8220;Hasta takibi, yaln\u0131zca tedavinin ba\u015far\u0131s\u0131n\u0131 de\u011fil, hastan\u0131n ya\u015fam kalitesini de do\u011frudan etkiler&#8221; dedi.<\/p>\n<p>Denizli \u00d6zel Egekent Hastanesi \u0130\u00e7 Hastal\u0131klar\u0131 Uzman\u0131 Dr. Ahmet Bilge, kanserle m\u00fccadelede erken te\u015fhisin ve d\u00fczenli hasta takibinin \u00f6nemine dikkat \u00e7ekti. G\u00fcn\u00fcm\u00fczde i\u00e7 hastal\u0131klar\u0131 yani dahiliye biriminin kanser taramalar\u0131nda daha ki\u015fiselle\u015ftirilmi\u015f y\u00f6ntemlerle hastalara yol g\u00f6sterdi\u011fini belirten Uzm. Dr. Ahmet Bilge, &#8220;Tarama y\u00f6ntemleri art\u0131k ki\u015fiye \u00f6zel planlan\u0131yor. Tarama kararlar\u0131 art\u0131k her hastan\u0131n ya\u015f\u0131, ya\u015fam tarz\u0131 ve risk fakt\u00f6rleri g\u00f6z \u00f6n\u00fcnde bulundurularak veriliyor. Bba\u011f\u0131rsak kanseri i\u00e7in 50 ya\u015f \u00fcst\u00fc bireylerde kolonoskopi ana y\u00f6ntem olarak tercih edilirken, ailesinde kanser \u00f6yk\u00fcs\u00fc olan veya ba\u015fka risk fakt\u00f6rleri ta\u015f\u0131yan ki\u015filerde y\u0131ll\u0131k gaitada gizli kan testi (FIT) gibi alternatifler de uygulanabiliyor. Akci\u011fer kanseri taramalar\u0131, 50-80 ya\u015f aras\u0131 ve uzun s\u00fcreli sigara i\u00e7mi\u015f bireylerde d\u00fc\u015f\u00fck dozlu bilgisayarl\u0131 tomografi y\u00f6ntemiyle y\u0131lda 1 yap\u0131labiliyor. Meme kanseri taramalar\u0131 ise 40 ya\u015f \u00fczerindeki kad\u0131nlarda genellikle iki y\u0131lda bir mamografi ile ger\u00e7ekle\u015ftiriliyor. Bu taramalar, i\u00e7 hastal\u0131klar\u0131 birimi taraf\u0131ndan radyoloji ve onkoloji uzmanlar\u0131yla i\u015f birli\u011fi i\u00e7inde y\u00fcr\u00fct\u00fcl\u00fcyor ve toplum sa\u011fl\u0131\u011f\u0131 hedefleriyle uyumlu hale getiriliyor&#8221; diye konu\u015ftu.<\/p>\n<p>&#8220;Her hastaya ayn\u0131 yakla\u015f\u0131m uygulanamaz&#8221;<br \/>\n<br \/>Dr. Ahmet Bilge, erken te\u015fhisin ba\u015far\u0131ya ula\u015fabilmesi i\u00e7in her hastaya \u00f6zel risk profili olu\u015fturulmas\u0131 gerekti\u011fini vurgulayarak; &#8220;Geli\u015fmi\u015f g\u00f6r\u00fcnt\u00fcleme teknikleri ve biyobelirte\u00e7ler, do\u011fru zamanda do\u011fru karar\u0131 almay\u0131 kolayla\u015ft\u0131r\u0131yor. Ancak bu testler, hastan\u0131n genel sa\u011fl\u0131k durumu ve ya\u015fam kalitesiyle uyumlu bir \u015fekilde entegre edilmeli&#8221; ifadelerini kulland\u0131.<\/p>\n<p>Tarama sonras\u0131 net bir yol haritas\u0131 \u015fart<br \/>\n<br \/>&#8220;Tarama sonu\u00e7lar\u0131na g\u00f6re izlenecek yol da en az te\u015fhis kadar \u00f6nemli&#8221; diyen Uzm. Dr. Ahmet Bilge Bilge, y\u00fcksek risk ta\u015f\u0131yan bireylerde taramalar\u0131n daha s\u0131k yap\u0131ld\u0131\u011f\u0131n\u0131, d\u00fc\u015f\u00fck riskli ki\u015filerde ise gereksiz testlerden ka\u00e7\u0131n\u0131larak hem hasta konforunun hem de sa\u011fl\u0131k kaynaklar\u0131n\u0131n korundu\u011funu belirtti.<\/p>\n<p>Hasta takibinin tedavinin sessiz kahraman\u0131 oldu\u011funun alt\u0131n\u0131 \u00e7izen Uzm. Dr. Ahmet Bilge, bu s\u00fcreci \u00fc\u00e7 ba\u015fl\u0131k alt\u0131nda \u00f6zetledi:<br \/>\n<br \/>&#8220;Kanser s\u00fcrecinde tedavi kadar \u00f6nemli olan bir di\u011fer konu da d\u00fczenli hasta takibi. Tedaviye verilen yan\u0131t\u0131n izlenmesi, ya\u015fanabilecek yan etkilerin y\u00f6netimi ve ya\u015fam tarz\u0131 de\u011fi\u015fiklikleriyle hastay\u0131 desteklemek b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor. Takip s\u00fcrecinde \u00f6zellikle ilk 2 y\u0131lda kontroller genellikle \u00fc\u00e7 ayda bir planlan\u0131yor. Daha sonraki y\u0131llarda ise hastan\u0131n durumu ve biyobelirte\u00e7 sonu\u00e7lar\u0131na g\u00f6re takip aral\u0131klar\u0131 yeniden d\u00fczenleniyor. Gerekti\u011finde g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemleriyle destek sa\u011flan\u0131yor. Hasta takibi, yaln\u0131zca tedavinin ba\u015far\u0131s\u0131n\u0131 de\u011fil, hastan\u0131n ya\u015fam kalitesini de do\u011frudan etkiler. Bu nedenle hastane i\u00e7inde etkin ileti\u015fim ve veri payla\u015f\u0131m\u0131 bir zorunluluktur&#8221;<br \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kanser vakalar\u0131nda hastaya \u00f6zel tarama ve risk profili olu\u015fturulmas\u0131n\u0131n tedaviyi ba\u015far\u0131ya ula\u015ft\u0131rd\u0131\u011f\u0131n\u0131 belirten Denizli \u00d6zel Egekent Hastanesi \u0130\u00e7 Hastal\u0131klar\u0131 Uzman\u0131 Dr. Ahmet Bilge, &#8220;Hasta takibi, yaln\u0131zca tedavinin ba\u015far\u0131s\u0131n\u0131 de\u011fil, hastan\u0131n ya\u015fam kalitesini de do\u011frudan etkiler&#8221; dedi. Denizli \u00d6zel Egekent Hastanesi \u0130\u00e7 Hastal\u0131klar\u0131 Uzman\u0131 Dr. Ahmet Bilge, kanserle m\u00fccadelede erken te\u015fhisin ve d\u00fczenli hasta takibinin \u00f6nemine&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48246,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","footnotes":""},"categories":[2],"tags":[],"class_list":["post-48245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik"],"_links":{"self":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/48245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48245"}],"version-history":[{"count":1,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/48245\/revisions"}],"predecessor-version":[{"id":48247,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/posts\/48245\/revisions\/48247"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=\/wp\/v2\/media\/48246"}],"wp:attachment":[{"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.egemtv.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}